Table 4.

Pathway activation in the context of clinicopathological data

Variable	Activation of ERBB/PI3K pathway		Mismatch Repair system functioning		TP53 mutated
	Number of positive samples (%)	p value	Number of positive samples (%)	p value	Number of positive samples (%)	p value
Menopausal status
Premenopausal	8/27 (29.6%)	0.73	6/28 (21.4%)	0.80	10/28 (35.7%)	0.64
Peri- and postmenopausal	98/368 (26.6%)		87/370 (23.5%)		149/371 (40.2%)
Age
≤50 years	11/41 (26.8%)	0.99	7/42 (16.7%)	0.28	12/42 (28.6%)	0.11
>50 years	95/355 (26.8%)		86/357 (24.1%)		148/358 (41.3%)
Obesity
Absent	57/195 (29.2%)	0.29	57/197 (28.9%)	0.009	83/197 (42.1%)	0.41
Present	49/200 (24.5%)		36/ 201 (17.9%)		77/202 (38.1%)
Diabetes
Absent	81/297 (27.3%)	0.69	65/299 (21.7%)	0.20	116/300 (38.7%)	0.35
Present	25/99 (25.3%)		28/100 (28.0%)		44/100 (44.0%)
Hypertension
Absent	41/138 (28.7%)	0.33	33/140 (23.6%)	0.93	64/140 (45.7%)	0.09
Present	65/258 (25.2%)		60/259 (23.2%)		96/260 (36.9%)
Histology
Type I	81/301 (26.9%)	0.60	62/303 (20.5%)	0.002	100/304 (32.9%)	<0.000001
Type II	10/40 (25.0%)		18/40 (45.0%)		29/40 (72.5%)
Grade 3	13/38 (34.2%)		8/38 (21.1%)		23/38 (60.5%)
Stage (FIGO*)
IA, IB, II	86/328 (26.2%)	0.70	73/331 (22.1%)	0.10	123/332 (37.1%)	0.01
IIIA, IIB, IIIC, IVA, IVB	18/63 (28.6%)		20/63 (31.8%)		34/63 (54.0%)
Cervical invasion
Absent	83/297 (28.0%)	0.28	68/299 (22.7%)	0.72	125/300 (41.7%)	0.17
Present	21/94 (22.3%)		25/95 (26.3%)		32/95 (33.7%)
Myometrial infiltration
≤1/2	49/194 (25.3%)	0.55	45/197 (22.8%)	0.47	71/198 (35.9%)	0.11
>1/2	55/197 (27.9%)		48/197 (24.4%)		86/197 (43.7%)
Metastases
Absent	87/326 (26.7%)	0.94	78/354 (22.0%)	0.02	127/330 (38.5%)	0.12
Present	16/61 (26.3%)		14/36 (38.9%)		30/61 (49.2%)

^*FIGO-International Federation of Gynecology and Obstetrics.